Tag: capital

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.

New York, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that Matthew Barry has joined the Company as its Director of Investor Relations.

Strategic federal initiative includes appointment of Jason Chasse, a US Federal and Military sales veteran with over 30 years of experience, as Director of Federal Sales.

BOCA RATON, FL, June 16, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced its support for the launch of a new dfdvSOL / SOL liquidity pool on Orca, one of the leading Solana-native decentralized exchanges. The pool, deployed on Orca’s flagship Concentrated Liquidity Market Maker (CLMM), introduces new utility and yield opportunities for dfdvSOL holders, while contributing to long-term growth in SOL per share (SPS).

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Southpoint Bancshares Inc. (OTCQX: SOUB), which operates primarily in the domestic commercial banking industry, has qualified to trade on the OTCQX® Best Market. Southpoint Bancshares Inc. upgraded to OTCQX from the Pink® market.

Former CEO Brings a Wealth of Industry Operations Expertise

Press Release

June 16, 2025

Signify share repurchase period update 

Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 49,249 shares in the period June 9 to June 13, 2025. The shares were repurchased at an average price of EUR 22.13 per share and an aggregate amount of EUR 1.1 million. Signify will use these repurchased shares to reduce the company’s capital.

The repurchases were made as part of the company’s share repurchase program, which was announced on February 4, 2025. The total number of shares repurchased under this program to date is 2,832,530 shares for a total consideration of EUR 56.56 million.

Details on the share buyback transactions can be found here.

Announcement marks the third phase of USD 100 million share buyback program